English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 15 June 2021, 08:00 HKT/SGT
Share:
    

Source: Eisai
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma

TOKYO, June 15, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma.

Zonegran is an antiepileptic drug (AED) originally created by Dainippon Pharmaceutical Co., Ltd. (currently Sumitomo Dainippon Pharma Co., Ltd.), for which Eisai holds the exclusive rights in a number of European countries, the Middle East, Russia, Australia, Canada, Mexico, and Asian countries. Under this agreement, Eisai will divest its rights associated with Zonegran in such European countries, the Middle East, Russia, and Australia to Advanz Pharma. Eisai will continue to act as the distributor in Russia, through its local affiliate Limited Liability Company Eisai, and Australia through its local affiliate Eisai Australia Pty. Ltd., for an agreed transition period. In addition, Eisai and Advanz Pharma have agreed to enter into a supply agreement under which Eisai's UK affiliate, Eisai Manufacturing Ltd., will serve as Advanz Pharma's supplier of Zonegran for the transferred territory for an agreed transition period.

Eisai will retain its rights to Zonegran in Canada, Mexico and Asian countries and continue to distribute the product in certain licensed Asian countries.

Eisai believes that this divestiture agreement with Advanz Pharma will lead to maximization of the antiepileptic agent's product value. In addition, the agreement will enable Eisai to strategically reallocate resources to other mid-to-long-term business growth areas so as to continue to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
Sept 15, 2021 11:00 HKT/SGT
エーザイ、国際的な環境イニシアチブ「RE100」に加盟
Sept 14, 2021 16:46 HKT/SGT
Eisai to Join The Global Environmental Initiative "RE100"
Sept 14, 2021 11:36 HKT/SGT
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
Sept 14, 2021 09:00 HKT/SGT
エーザイ、欧州臨床腫瘍学会年次総会におけるエーザイのがん領域の開発品・製品等に関する演題について
Sept 13, 2021 15:37 HKT/SGT
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"
More news >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575